MicroSENSE - Antibiotic Discovery and Development

Murine Model of Infection: Neutropenic Thigh

Model Overview

Following initial in vitro screening to assess the efficacy, range and mechanism of antibacterial and antifungal activity and resistance, quickly transition your compound evaluation to in vivo models. The neutropenic thigh mouse model has been utilized extensively to test antimicrobial drug candidates. This model allows the quantitative comparison of various classes of antibacterial or antifungal agents utilizing different dosing regimens under neutropenic conditions. ImQuest has optimized the neutropenic thigh mouse model and it is available for testing both wild type and resistant bacterial strains based on the needs of our clients.


  • Determination of in vivo efficacy of candidate antimicrobial drugs against clinical and antibiotic resistant strains
  • Comparison of antimicrobial agents with FDA approved compounds of similar class
  • Modulation of antibiotic time of addition
  • Parallel assessment of PK/PD measurements, dose and dosing interval related to efficacy and the emergence of antibacterial resistance

Assay Customization

Numerous wild type, resistant, and clinical strain are available for use in the mouse model. While the model has been optimized with a representative and client-specific strains, initial pilot studies to assess bacterial inoculum and growth kinetics are often necessary. Client derived laboratory or clinical strains can be utilized in the model upon request. Variables in the model that can be customized include, route of drug administration, selection of positive control, duration of assay, animal dosing regimen, and assay endpoints assessed.

Contact us to learn more and let our microbiology and in vivo modeling experts help design and implement a study to fit your needs. Custom in vivo models are also available upon request.

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides service to evaluate the potential efficacy of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory disease, including in vitro toxicology and pharmaceutical product characterization services.